The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008, China.
Mol Cancer. 2019 Nov 5;18(1):154. doi: 10.1186/s12943-019-1092-1.
Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7) and light chains are in active development for therapy of refractory /relapsed (RR) MM. CD19- targeted CAR T cells in conjunction with autologous stem cell transplantation also showed activity in RRMM. Dual- target CAR T cells are in clinical trials for RRMM. This review summarized the recent updates of ongoing CAR T clinical trials for multiple myeloma.
蛋白酶体抑制剂、免疫调节剂和单克隆抗体极大地改变了多发性骨髓瘤（MM）的自然病程。然而，大多数患者最终会复发并死于该疾病。嵌合抗原受体（CAR）修饰的 T 细胞靶向 B 细胞成熟抗原（BCMA）、CD138、CS1 糖蛋白抗原（SLAMF7）和轻链，正在积极开发用于治疗难治性/复发性（RR）MM。CD19 靶向 CAR T 细胞联合自体干细胞移植在 RRMM 中也显示出活性。双靶点 CAR T 细胞正在 RRMM 的临床试验中进行研究。本文总结了正在进行的多发性骨髓瘤 CAR T 临床试验的最新进展。
Zotero 插件